First Eagle Investment Management, LLC filed an amended Schedule 13G reporting beneficial ownership of 3,339,101.48 shares of IPG Photonics Corp common stock, representing 7.87% of the shares believed outstanding. First Eagle has sole voting power over 3,012,312 shares and sole dispositive power over 3,339,101.48 shares, with no shared voting or dispositive power.
The First Eagle Global Fund, a registered investment company advised by First Eagle, may be deemed to beneficially own 2,350,213 of these shares, or 5.54% of IPG Photonics’ common stock. The shares are held principally on behalf of investment advisory clients, who have the right to receive dividends and sale proceeds.
IPG Photonics Corp shareholder IP Fibre Devices Ltd, a ten percent owner, reported selling 27,000 shares of common stock on July 31, 2026. The sales were executed in multiple open-market transactions at weighted average prices of $85.76 and $86.14, with additional blocks at $87.45 and $88.59, under a Rule 10b5-1 trading plan adopted March 17, 2026.
Eugene A. Scherbakov, a director and 10% owner of IPG Photonics Corp, reported selling 1,524 shares of common stock on July 31, 2026. The four non-derivative sales were executed at weighted average prices from $85.72 to $88.68 per share, in price ranges detailed for each trade. All transactions were effected under a Rule 10b5-1 trading plan adopted on March 17, 2026.
IPG Photonics reported Q2 2026 net sales of about $278.6M, up 11.1% year over year, with first‑half sales near $544.1M, up 13.7%. Growth was driven by Industrial Solutions, especially welding, cleaning, marking and services, while Advanced Solutions declined. Gross margin improved to 40.4% from 37.3%, helped by lower product costs and $4.7M of tariff refunds that added about 170 basis points, partly offset by higher unabsorbed manufacturing costs.
Despite stronger revenue, net income fell to $5.2M in Q2 and $6.8M for the first half, constrained by a high tax rate and non‑recurring items. The company booked a $17.6M impairment tied to the planned sale of its Belarus operations, now classified as held for sale, and a $13.3M patent litigation settlement with Trumpf. Operating cash flow strengthened to $32.3M in the first half, with $399.2M of cash and $472.1M of short‑term investments and no borrowings under a revolving credit facility. After quarter‑end IPG signed a put option to acquire Lumibird Medical for €300,000 plus up to €50,000 earn‑out, expected to close in the fourth quarter of 2026 subject to French approvals.
IPG Photonics reported second quarter 2026 revenue of $278.6 million, up 11% year over year, with GAAP gross margin improving to 40.4%. Operating income was $4.5 million, and GAAP net income declined 21% to $5.2 million, or $0.12 per diluted share, partly reflecting impairment charges of $17,574 (in thousands) and a 58% tax rate.
Industrial Solutions revenue grew 16% year over year and represented 85% of total sales, while Advanced Solutions revenue decreased. Emerging growth products contributed 58% of revenue. Adjusted gross margin was 40.7%, adjusted EBITDA rose 54% to $48.5 million, and adjusted EPS increased 93% to $0.58. The company generated $37.8 million of operating cash flow and invested $20.7 million in capital expenditures. For the third quarter of 2026, guidance calls for revenue of $265–$295 million, adjusted gross margin of 37.5%–40.5%, adjusted operating expenses of $92–$95 million, adjusted EPS of $0.30–$0.60, and adjusted EBITDA of $35–$51 million.
Amendment No. 7 to Schedule 13D for IPG Photonics Corporation updates beneficial ownership information for several major holders of the company’s common stock. Reported percentages are calculated using 42,443,616 shares of common stock outstanding as of May 4, 2026.
The Valentin Gapontsev Trust I reports beneficial ownership of 6,670,283 shares, or 15.7% of the class. Angelo P. Lopresti reports 8,095,986 shares (19.1%). IQ EQ Trust Company, U.S., LLC reports 8,328,919 shares (19.6%). Eugene A. Shcherbakov reports 14,577,710 shares, representing 34.3% of IPG Photonics’ common stock.
IPG Photonics Corporation has a significant shareholder disclosure from IP Fibre Devices (UK) Ltd, which filed an amended Schedule 13G. The reporting person, organized under the laws of the United Kingdom, reports beneficial ownership of 6,463,302 shares of IPG Photonics common stock, par value $0.0001 per share.
This holding represents 15.2% of the outstanding common stock. IP Fibre Devices (UK) Ltd reports sole voting power and sole dispositive power over all 6,463,302 shares, with no shared voting or dispositive power. The filing is signed by Dr. Eugene A. Scherbakov as Managing Director of the reporting person.
IPG Photonics Corp ten percent owner Valentin Gapontsev Trust I reported selling a total of 56,316 shares of common stock on July 21, 2026 in four sale transactions. The weighted average prices were $100.08, $101.20, $102.04 and $103.00 per share, each covering multiple trades within stated price ranges. The sales were effected pursuant to a pre-arranged Rule 10b5-1 trading plan adopted on March 17, 2026.
IPG Photonics Corporation agreed a Put Option Agreement with Lumibird S.A. for the proposed acquisition of 100% of Lumibird Medical for a cash purchase price of €300 million, on a cash-free, debt-free basis, plus up to €50 million earnout tied to 2026–2027 performance. IPG Photonics plans to fund the deal with cash on hand. After completion of the required French works council consultation and the seller’s exercise of the put, IPG Photonics is irrevocably committed to sign a share purchase agreement, with closing targeted in the fourth quarter of 2026, subject to customary conditions and authorization under the French foreign direct investment regime.
The agreements include exclusivity for IPG Photonics, warranty and indemnity insurance covering many seller warranties, capped seller liability for business warranties, and three-year non-compete and non-solicitation provisions on the seller. Lumibird Medical generated 2025 revenue of €112.2 million and EBITDA of €24.1 million, and IPG Photonics describes the business as high-margin and expects the acquisition to be accretive to gross margin, EBITDA and adjusted EPS while adding approximately $1 billion to the Advanced Solutions addressable market. A supplemental investor presentation indicates the €300 million price equals 15.9x 2025 adjusted EBITDA of €18.9 million and that the combined medical businesses would have about $204 million of 2025 sales.
IPG Photonics Corp large shareholder IP Fibre Devices Ltd, a ten percent owner, reported open-market sales of a total of 65,700 shares of common stock on June 29, 2026.
The shares were sold in multiple transactions at prices ranging from $99.55 to $106.87 per share, with several tranches reported at weighted-average prices between about $100.19 and $106.40. These sales were executed pursuant to a Rule 10b5-1 trading plan adopted on March 17, 2026. Following the transactions, IP Fibre Devices Ltd directly holds 6,463,302 shares of IPG Photonics common stock.